---
title: "MIRM: Robust sales growth and a rich late-stage pipeline position the company for five potential approvals by 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291467602.md"
description: "Net product sales are projected to reach $660–680M in 2026, driven by strong growth in rare liver and genetic disease medicines. Multiple late-stage pipeline assets, including LIVMARLI, Volixibat, Brelovitug, and Zilurgisertib, are advancing toward regulatory milestones, with five potential approvals or label expansions expected by 2027.Original document: Mirum Pharmaceuticals, Inc. [MIRM] Slides Release — Jul. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-01T22:24:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291467602.md)
  - [en](https://longbridge.com/en/news/291467602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291467602.md)
---

# MIRM: Robust sales growth and a rich late-stage pipeline position the company for five potential approvals by 2027

Net product sales are projected to reach $660–680M in 2026, driven by strong growth in rare liver and genetic disease medicines. Multiple late-stage pipeline assets, including LIVMARLI, Volixibat, Brelovitug, and Zilurgisertib, are advancing toward regulatory milestones, with five potential approvals or label expansions expected by 2027.

Original document: Mirum Pharmaceuticals, Inc. \[MIRM\] Slides Release — Jul. 1 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MIRM.US](https://longbridge.com/en/quote/MIRM.US.md)

## Related News & Research

- [Mirum SVP, Global Controller Jolanda Howe sells 1,840 shares for $193,733.6](https://longbridge.com/en/news/295010149.md)
- [What is HC Wainwright's Forecast for MIRM FY2028 Earnings?](https://longbridge.com/en/news/294201985.md)
- [Mirum Pharmaceuticals Q2 sales rise, lifts outlook](https://longbridge.com/en/news/295007489.md)
- [Palantir’s next leap - why its stock keeps surprising investors](https://longbridge.com/en/news/294605106.md)
- [Intuit (INTU) Posted Strong Q3 Results, Is The Stock Still Trading At A Discount?](https://longbridge.com/en/news/294604940.md)